The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review

This narrative review explores the potential therapeutic role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in the management of Polycystic Ovary Syndrome (PCOS). PCOS is a multifaceted challenge affecting women, often associated with genetic susceptibility, obesity, and insulin resistan...

Full description

Bibliographic Details
Published in:	Quality in Sport
Main Authors:	Kamil Turlej, Dmytro Kowalczuk, Viktoryia Kasianik, Darya Lazitskaya, Mykola Sobchynskyi, Valeryia Milasheuskaya, Andrii Myrnyi, Iga Kiełbaszewska, Natallia Surosz, Katsiaryna Miraniuk
Format:	Article
Language:	English
Published:	Nicolaus Copernicus University in Toruń 2025-07-01
Subjects:	PCOS GLP-1 receptor agonists inferitility maternal obesity
Online Access:	https://apcz.umk.pl/QS/article/view/61264

Similar Items

Effectiveness, Limitations, and Future Perspectives of CAR-T Cell Therapy in Solid Tumor Treatment: A Narrative Review
by: Dmytro Kowalczuk, et al.
Published: (2025-05-01)

E-Cigarettes: Biological Effects, Addiction Risk, and Public Health Challenges – A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-05-01)

Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies
by: Valeryia Milasheuskaya, et al.
Published: (2025-07-01)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention
by: Xiong C, et al.
Published: (2024-02-01)

Impact of dramatic weight loss with the new injectable medications on reproduction in healthy non–polycystic ovary syndrome obese women
by: Zaher Merhi, M.D., H.C.L.D.
Published: (2025-03-01)

Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in poly cystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials
by: Kannan Sridharan, et al.
Published: (2025-05-01)

Fasting GLP-1 Levels in Women with PCOS and CAH
by: Robeva R., et al.
Published: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome
by: Dorte Glintborg, et al.
Published: (2017-06-01)

The current possible treatment approaches of Polycystic Ovary Syndrome (PCOS)
by: Justyna Lipińska, et al.
Published: (2024-02-01)

Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice
by: Dawood Khan, et al.
Published: (2022-11-01)

Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
by: Feng Jia Nuo, et al.
Published: (2024-08-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

Radiation-induced oxidative injury of the ileum and colon is alleviated by glucagon-like peptide-1 and -2
by: Mustafa Deniz, et al.
Published: (2015-04-01)

L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis
by: Sarah E. Martchenko, et al.
Published: (2021-12-01)

Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
by: Tyler S. Oesterle, et al.
Published: (2025-06-01)

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes
by: Leigh Perreault, et al.
Published: (2024-06-01)

Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases
by: Sihui Deng, et al.
Published: (2025-10-01)

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury
by: Ali Ismaeil, et al.
Published: (2022-06-01)

Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity
by: Jennifer Wilbrink, et al.
Published: (2024-12-01)

Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures
by: Smriti Jain, et al.
Published: (2024-09-01)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
by: Syed Faizan Mehdi, et al.
Published: (2023-05-01)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
by: Isabella Zaffina, et al.
Published: (2023-02-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Glucagon-like Peptide-1 Levels and Related Parameters in Rheumatoid Arthritis Patients Prone to Atherosclerosis
by: Noorhan K. Shafeeq, et al.
Published: (2017-06-01)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024-08-01)

Serum Ghrelin and Glucagon-like Peptide 1 Levels in Children with Prader-Willi and Bardet-Biedl Syndromes
by: Doğa Türkkahraman, et al.
Published: (2024-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
by: Stav Brown, et al.
Published: (2024-09-01)

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
by: Juan Pang, et al.
Published: (2022-11-01)

Diagnosis and Treatment of Adolescent Polycystic Ovary syndrome:A Review
by: Zhang Y, et al.
Published: (2025-02-01)

Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important than the Rotterdam Phenotype in Influencing the Metabolic Status
by: Enrico Carmina, et al.
Published: (2022-09-01)

Need to Introduce the Finding of Obesity or Normal Body Weight in the Current Diagnostic Criteria and in the Classification of PCOS
by: Enrico Carmina
Published: (2022-10-01)

Glucagon-like peptide-1 receptor agonists in neoplastic diseases
by: Lisan Ji, et al.
Published: (2024-09-01)

Effect of integrated approach of yoga and naturopathy on polycystic ovarian syndrome: A case study
by: Ragini Shrivastava, et al.
Published: (2022-01-01)

Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation
by: Goh Kodama, et al.
Published: (2025-04-01)

A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists
by: En-Hao Hu, et al.
Published: (2024-02-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023-02-01)